MarketCap
Facebook
X
Telegram
BiomX Financial Ratios 2025-2011 | PHGE
Brief overview of BiomX 's valuation and returns
This overview follows the five latest available observations from 2021 through 2025.
The latest available valuation ratios are EV/EBITDA 0.31x (median 0.71x), P/B 1.48x (median 0.2x). On average, this basket is 285.9% above its own five-year medians. The market is pricing in elevated future expectations.
Current measures of operating quality are ROE 27.8%, ROA -6.3%, ROCE 69.6%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
Current PEG is 0.59x; the market pays comparatively little per unit of expected growth.
Valuation takeaway
BiomX 's multiples are demanding relative to current business quality. Material improvement is needed to justify them.
Annual Financial Ratios BiomX
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.2 | -0.2 | -0.1 | -0.3 | -1.1 | -5.0 | 60.2 | - | - | - | - | - | - | - | - |
EPS |
22.2 | 25.4 | 5.1 | 0.9 | 1.4 | 1.3 | 3.7 | 7.6 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
4.2 M | -13.2 M | -13 M | -22.1 M | -23.9 M | 128 M | -50.5 M | 40.6 K | - | - | - | - | - | - | - |
EBITDA per Share |
-23.6 | -61.1 | -4.77 | -0.83 | -1.26 | -1.2 | -0.2 | - | - | - | - | - | - | - | - |
EV/EBITDA |
-0.1 | 0.3 | 0.5 | 0.9 | 1.0 | -4.2 | -51.9 | - | - | - | - | - | - | - | - |
PEG |
-0.0 | -0.0 | - | - | - | -0.08 | 0.59 | - | - | - | - | - | - | - | - |
P/B |
1.5 | 0.1 | 0.1 | 0.2 | 0.5 | 2.6 | 0.3 | - | - | - | - | - | - | - | - |
P/CF |
-0.3 | -0.1 | -0.1 | -0.3 | -1.4 | -6.0 | -102.2 | - | - | - | - | - | - | - | - |
ROE % |
2780.26 | -73.41 | -849.37 | -134.59 | -76.21 | -52.35 | 0.49 | - | - | - | - | - | - | - | - |
ROA % |
-625.96 | -41.00 | -104.55 | -62.19 | -46.45 | -42.76 | 0.49 | - | - | - | - | - | - | - | - |
ROCE % |
6957.38 | -127.33 | -182.98 | -72.41 | -52.97 | -47.88 | -0.57 | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | - | - | 8.5 | 2.0 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios BiomX
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
7.38 | 0.29 | 0.19 | 0.33 | - | -0.31 | -0.14 | 2.78 | - | 1.3 | 0.12 | 0.2 | - | 0.23 | 0.25 | 0.27 | - | 0.37 | 0.3 | 0.35 | - | 0.38 | 0.27 | 0.26 | - | 2.69 | 2.5 | -0.25 | - | - | -0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.41 | - | - | -0.33 | - | - | - | -1.05 | - | - | - | -0.19 | - | -0.21 | -0.23 | -0.24 | - | -0.3 | -0.25 | -0.33 | - | -0.31 | -0.23 | -0.24 | - | -2.16 | -1.93 | -0.25 | -0.01 | - | -0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
2022.35 | -124.74 | -21.02 | 192.03 | 223.29 | 126.34 | 60.48 | 4.78 | -176.77 | -202.29 | -128.19 | -108.19 | -68.80 | -87.57 | -77.14 | -69.86 | -49.45 | -64.82 | -56.84 | -52.01 | -36.44 | -41.48 | -30.58 | -20.13 | -9.86 | -9.84 | -4.81 | -0.13 | -3.95 | -0.01 | 0.21 | -4.17 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-656.41 | -51.59 | -10.05 | -15.42 | 1.36 | -22.56 | -54.17 | -76.05 | -54.82 | -67.88 | -56.78 | -53.12 | -37.76 | -50.03 | -48.86 | -48.57 | -36.69 | -49.25 | -45.80 | -42.29 | -29.76 | -34.39 | -25.93 | -17.43 | -9.04 | -9.02 | -5.40 | -1.28 | 0.02 | -1.00 | 0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-245.41 | -106.42 | -81.52 | -75.77 | -55.69 | -94.14 | -92.47 | -96.50 | -78.87 | -93.61 | -69.28 | -61.97 | -42.08 | -55.58 | -54.39 | -54.69 | -41.47 | -55.44 | -52.05 | -47.94 | -33.53 | -38.95 | -29.71 | -20.31 | -10.87 | -10.91 | -5.50 | -1.10 | -4.54 | -0.01 | -0.33 | -4.17 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
0.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 122.7 | 105.8 | 139.7 | 83.7 | 1.6 | 1730.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company BiomX , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
